Vantia Ltd: Clinical Trials

12 trials sponsored by Vantia Ltd, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 completed. 8 Phase 1, 5 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 18Completed 8
Phase 25Completed 5
Phase 31Completed 1

Follow Vantia Ltd: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH)
Fedovapagon 2 mg, Placebo - Nocturia
Phase 2 / Phase 3CompletedVantia Ltd4322016-03-012018-10-31
A Study in Healthy Volunteers to Assess the Effect of Fedovapagon on the QT/QTC Interval
Fedovapagon, Moxifloxacin, Placebo (for fedovapagon) - Healthy
Phase 1CompletedVantia Ltd432015-10-012016-01-06
Study in Healthy Male Subjects to Evaluate the Effect of Itraconazole and Rifampicin on the PK of Fedovapagon
fedovapagon, Itraconazole, rifampicin - Nocturia
Phase 1CompletedVantia Ltd292015-05-012015-07-30
Dose Range Finding Study of Fedovapagon in Men With Nocturia
fedovapagon 1 mg, fedovapagon 2 mg, fedovapagon 4 mg - Nocturia
Phase 2CompletedVantia Ltd3582012-08-012014-06-20
Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH)
VA106483 - Nocturia, Benign Prostatic Hypertrophy (BPH)
Phase 1CompletedVantia Ltd302011-03-012011-08-02
VA106483 Dose Response in Females
VA106483, Placebo - Nocturia
Phase 1CompletedVantia Ltd212010-07-012010-12-01
Efficacy Study of VA106483 in Males With Nocturia.
VA106483 - Nocturia
Phase 2CompletedVantia Ltd1522009-12-012014-06-20
VA111913 Dysmenorrhoea Efficacy and Safety Proof of Concept
VA111913 TS and placebo - Primary Dysmenorrhea
Phase 2CompletedVantia Ltd1462009-08-012014-05-22
VA106483 Dose Response Study in Elderly Males
VA106483, Placebo - Nocturia
Phase 1CompletedVantia Ltd102009-06-012018-05-23
VA106483 and Alpha Blocker Interaction Study in Elderly Males
VA106483, Placebo - Nocturia
Phase 1CompletedVantia Ltd122009-04-012009-11-25
VA111913 TS: First in Human Study
VA111913 TS / placebo - Dysmenorrhea
Phase 1CompletedVantia Ltd982008-09-012009-06-25
Efficacy and Safety of VA106483 in Elderly Males
VA106483, Sugar pill - Nocturia
Phase 1 / Phase 2CompletedVantia Ltd272008-08-012018-10-31

Conditions studied

Nocturia (10)  ·  Dysmenorrhea (2)  ·  Prostatic Hyperplasia (2)  ·  Hyponatremia (1)  ·  Pain (1)

Interventions

Sugars (2)  ·  Itraconazole (1)  ·  Moxifloxacin (1)  ·  Rifampin (1)

Countries

United States (6)  ·  United Kingdom (4)  ·  Germany (3)

Top investigators

Ralph Schutz (2)  ·  Aris Nikas (1)  ·  Bruce Rankin (1)  ·  Chris Ng (1)  ·  David Beccia (1)  ·  David Bell (1)  ·  Earl Martin (1)  ·  Elizabeth Houser (1)  ·  Evan Goldfischer (1)  ·  Georg Golor, PD Dr med (1)  ·  Georg Golor, PD Dr. med. (1)  ·  H. David Mitcheson (1)  ·  Hilary McElwaine-Johnn, BSc, ASM, MBBS, MRCP, MFPM (1)  ·  Howard Hezmall (1)  ·  Joseph Parkhurst (1)